Synergistic interactions of endogenous opioids and cannabinoid systems

Brain Research

Volumn 848, Issue 1-2, 1999, Pages 183-190

  Welch, Sandra P ^a   Eads, Micah ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Analgesia; Cannabinoid; Dynorphin; Endocannabinoid; Enkephalin; Opioid

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; DEXTRONANTRADOL; DYNORPHIN; ENKEPHALIN; LEVONANTRADOL; OPIATE; RIMONABANT;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; INTRATHECAL DRUG ADMINISTRATION; MALE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; MALE; OPIOID PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033458086     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01908-3     Document Type: Article

References (50)

1. 9-THC: Dose-response analysis and receptor characterization. J. Pharmacol. Exp. Ther. 289:1999;859-867.
2. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
3. Deadwyler S.A., Hampson R.E., Bennet B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptor Channels. I:1993;121-134.
4. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
5. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50:1955;1096-1121.
6. 9-THC, CP55,940 and WIN 55,212. J. Pharmacol. Exp. Ther. 271:1994;1383-1390.
7. 9-THC. J. Pharmacol. Exp. Ther. 272:1995;699-707.
8. Gilbert P.E. A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dogÿ J. Clin. Pharmacol. 21:1981;311S-319S.
9. Harris L.S., Pierson A.K. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 143:1990;141-148.
10. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
11. 5] enkephalin. Eur. J. Pharmacol. 165:1989;1-10.
12. Hollt V. Opioid peptide processing and receptor selectivity. Ann. Rev. Pharmacol. Tox. 26:1986;59-77.
13. Lichtman A.H., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl). 119:1995;282-290.
14. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20:1999;287-294.
15. B.R. Martin, S.P. Welch, M. Abood, Progress toward understanding the cannabinoid receptor and its second messenger systems, in: J.T. August, M.W. Anders, F. Murad (Eds.), Advances in Pharmacology, Academic Press, 1994, pp. 341-397.
16. 9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development, Eur. J. Pharmacol. (1999) in press.
17. D.J. Mason, S.P. Welch, Cannabinoid modulation of dynorphin A: Correlation to cannabinoid-induced antinociception, Eur. J. Pharmacol. (1999) in press.
18. Matsuda L.A., Lolait S.J., Bowstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
19. Mechoulam R., Hanus L., Martin B.R. Search for endogenous ligands of the cannabinoid receptor. Biochem. Pharmacol. 48:1994;1537-1544.
20. Miaskowski C., Taiwo Y.O., Levine J.D. Kappa and delta agonists synergize to produce potent analgesia. Brain Res. 509:1990;165-168.
21. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
22. Nakazawa T., Ikeda M., Kaneko T., Yamatsu K., Kitagawa K., Kiso Y. Bestatin potentiates the antinociception but not the motor dysfunction induced by intracerebrally administered dynorphin-B in mice. Neuropeptides. 13:1989;277-283.
23. Noyes R. Jr., Brunk S.F., Avery D.A.H., Canter A.C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18:1975;84-89.
24. Pertwee R., Griffin G., Hanus L., Mechoulam R. Effects of two fatty acid ethanolamides on mouse vasa deferentia. Eur. J. Pharmacol. 259:1994;115-120.
25. Piomelli D., Beltramo M., Giuffrida A., Stella N. Endogenous cannabinoid signaling. Neurobiol. Dis. 5:1998;462-473.
26. 9-THC in the spinal cord. Brain Res. 689:1995;157-158.
27. Pugh G.J., Mason D.J., Combs V., Welch S.P. Involvement of dynorphin B in the antinociceptive effects of CP55,940, in the spinal cord. J. Pharmacol. Exp. Ther. 281:1997;730-737.
28. 9-THC and morphine in the spinal cord. J. Pharmacol. Exp. Ther. 279:1996;608-616.
29. Raft D., Gregg J., Ghia J., Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin. Pharmacol. Ther. 21:1977;26-33.
30. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., LeFur G. SR141716A, a potent and selective antagonist of the cannabinoid receptor. Fed. Eur. Biochem. Soc. Lett. 350:1994;240-244.
31. Rinaldi-Carmona M., Barth F., Millan J., Deroq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Portier M., Shire D., Breliere J.C., LeFur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
32. Roerig S.C., Fujimoto J.M. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interaction between delta and kappa agonists for antinociception in mice. J. Pharmacol. Exp. Ther. 249:1989;762-768.
33. 9-tetrahydrocannabinol. Pharm. Biochem. Behav. 51:1995;731-737.
34. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., LeFur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
35. 9-tetrahydrocannabinol and anandamide antinociception in non-arthritic and arthritic rats. Pharmacol. Biochem. Behav. 60:1998;183-191.
36. 9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 60:1998;559-566.
37. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
38. 9 tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268:1994;1382-1387.
39. Song Z.H., Takemori A.E. Involvement of spinal kappa opioid receptors in the antagonistic effect of dynorphins on morphine antinociception. Life Sci. 48:1991;1447-1453.
40. Spampinato S., Romualdi P., Candeletti S., Cavicchini E., Ferri S. Distinguishable effects of intrathecal dynorphins, somatostatin, neurotensin, and s-calcitonin nociception and motor function in the rat. Pain. 35:1988;94-104.
41. B.F. Thomas, A.F. Gilliam, D.F. Burch, M.J. Roche, H.H. Seltzman, Comparative binding analysis of cannabinoid agonists and antagonists: Evidence supporting neuronal cannabinoid receptor subtypes, Int. Cannabinoid. Res. Soc. Symp., 1977.
42. Tseng L.F. Intracerebroventricular administration of beta-endorphin releases immunoreactive methionine enkephalin from the spinal cord of cats, guinea pigs and mice. Neuropharmacology. 28:1989;1333-1339.
43. Welch S.P. Modulation of cannabinoid-induced antinociception by nor-binaltorphimine, but not ICI 174,864, in mice. J. Pharmacol. Exp. Ther. 265:1993;633-640.
44. Welch S.P. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Dep. 45:1997;39-45.
45. 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273:1995;1235-1244.
46. Welch S.P., Huffman J.W., Lowe J. Differential Blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther. 286:1998;1301-1308.
47. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception following intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
48. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally-administered cannabinoids alone, and in combination with morphine in mice. J. Pharmacol. Exp. Ther. 262:1992;10-18.
49. Wiley J.L., Barrett R.L., Lowe J., Balster R.L., Martin B.R. Discriminative effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 34:1995;669-676.
50. Yaksh T.L. The antinociceptive effect of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharm. 21:1981;334-340.